Schnieders Capital Management LLC Makes New $202,000 Investment in Novartis AG $NVS

Schnieders Capital Management LLC bought a new position in Novartis AG (NYSE:NVS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,671 shares of the company’s stock, valued at approximately $202,000.

Several other institutional investors and hedge funds have also bought and sold shares of NVS. Brighton Jones LLC boosted its position in Novartis by 76.5% in the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after purchasing an additional 2,666 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Novartis by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 6,524 shares of the company’s stock valued at $727,000 after buying an additional 1,500 shares in the last quarter. Stonegate Investment Group LLC purchased a new position in shares of Novartis during the 1st quarter valued at about $277,000. Live Oak Private Wealth LLC lifted its position in shares of Novartis by 1.6% during the 1st quarter. Live Oak Private Wealth LLC now owns 76,684 shares of the company’s stock valued at $8,549,000 after buying an additional 1,207 shares in the last quarter. Finally, Acorn Creek Capital LLC lifted its position in shares of Novartis by 4.2% during the 1st quarter. Acorn Creek Capital LLC now owns 3,511 shares of the company’s stock valued at $391,000 after buying an additional 143 shares in the last quarter. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Price Performance

NVS stock opened at $131.78 on Tuesday. Novartis AG has a one year low of $96.06 and a one year high of $133.55. The company’s fifty day moving average price is $126.80 and its 200-day moving average price is $118.80. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.62 and a current ratio of 0.82. The company has a market capitalization of $278.38 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 1.82 and a beta of 0.64.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group reaffirmed a “sell” rating and set a $118.00 price objective (down from $119.00) on shares of Novartis in a research report on Friday, September 12th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a research report on Thursday, August 21st. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research note on Wednesday, October 8th. Morgan Stanley upgraded Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target for the company in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Novartis presently has a consensus rating of “Hold” and an average price target of $120.33.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.